Quarterly ResultApr 30, 2026, 07:07 AM
NVCR Q1 Revenue +12% to $174.1M; Net Loss $71.1M; Optune Pax Launched
AI Summary
NovoCure reported Q1 2026 net revenues of $174.1 million, a 12% increase year-over-year, driven by global growth in Optune Gio. The company posted a net loss of $71.1 million, primarily due to a $43 million share-based compensation expense triggered by the U.S. FDA approval of Optune Pax. Optune Pax was approved by the U.S. FDA and launched for locally advanced pancreatic cancer, with 169 prescriptions received. The company also updated its full-year 2026 revenue guidance to $690 million - $710 million and Adjusted EBITDA guidance to $(15) million - $0 million.
Key Highlights
- Optune Pax approved by U.S. FDA and launched for locally advanced pancreatic cancer.
- Q1 2026 net revenues increased 12% year-over-year to $174.1 million.
- Q1 2026 net loss was $71.1 million, with loss per share of $0.62.
- General and administrative expenses rose 92% to $85.9 million, including a $43 million share-based compensation expense.
- Gross margin improved to 78% from 75% in the prior year.
- Total active patients on TTFields therapy globally reached 4,791 as of March 31, 2026.
- Full-year 2026 net revenue guidance updated to $690M-$710M (previously $675M-$705M).
- Full-year 2026 Adjusted EBITDA guidance updated to $(15)M-$0M (previously $(20)M-$0M).